Two-stage design and 'forced bioequivalence' [Two-Stage / GS Designs]

posted by Mikalai  – Belarus, 2018-06-06 08:28 (906 d 18:51 ago) – Posting: # 18854
Views: 3,693

(edited by Mikalai on 2018-06-06 08:44)

Dear all,
We plan to conduct a sequential (two stage) BE study, and I am concerned with "forced bioequivalence". Specifically, if we obtain non-equivalent results in the first stage with very low power and should recruit more volunteers, how can we protect ourselves from getting into "forced bioequivalence"? In other words, how can we differentiate between underpowered trials and non-equivalent results in the sequential BE? And how can we put this (protection against "forced bioequivalence") in the protocol not to raise many questions from regulators?
Any suggestions and advice will be appreciated.

Complete thread:

 Admin contact
21,216 posts in 4,427 threads, 1,481 registered users;
online 20 (0 registered, 20 guests [including 8 identified bots]).
Forum time: Sunday 02:19 CET (Europe/Vienna)

Half the harm that is done in this world
Is due to people who want to feel important.    T. S. Eliot

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz